share_log

GlaxoSmithKline | 6-K: Positive Ruby Phase Iii Data Show Potential for Jemperli (Dostarlimab) Combinations in More Patients with Primary Advanced or Recurrent Endometrial Cancer

SEC announcement ·  Mar 18 09:59
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more